Nick has spent the majority of his career helping companies navigate complex regulatory risk in the Food, Drug, and Medical Device categories. After a career in Government at the Federal and Provincial levels, he has served as Head of Corporate Affairs at JUUL Labs Canada, Government Affairs & Public Leader at GE Healthcare and Director of Public Affairs for Red Bull Canada.
Board of Directors
Ms. Butts is a lawyer, entrepreneur, and a seasoned executive with a strong track record in driving positive change and growth within leading organizations. Currently, Ms. Butts serves as an independent member of the Board of Directors of Canada Goose Inc.; an independent member of the Board of Directors of Aphria Inc.; Chair of The Walrus Foundation Board of Directors; and as a member of the Board of Governors and Audit Committee of the University of Windsor. She also holds several Board Advisory roles including with Bayshore Home Healthcare.
Fraser Macdonald is a corporate lawyer and public affairs consultant based in Toronto. Fraser has provided advice to blue-chip clients across three continents. Specializing in banking and finance law, Fraser has worked at top-tier international law firms in Toronto, Australia and London, UK. He has a deep understanding of the regulatory landscape for financial institutions and other businesses both within Canada and internationally. He is currently a Senior Associate at a leading boutique government relations consultancy firm in Toronto.
Fraser holds a B.A. (Hons) in History from Queen’s University and a Juris Doctor (with Honours) from Bond University.
Perry Tsergas has worked in the world of Canadian politics, advocacy and communications for over two decades. He is the co-founder, President & CEO of spark*advocacy, an Ottawa-based public affairs marketing and communications firm. Perry has partnered with hundreds of start-ups, corporations, associations, unions, charities, NGOs and coalitions on communications initiatives of all shapes and sizes. Over the years he has been involved in supporting dozens of health, pharma/biotech and wellness related clients, and has taken a keen interest in how innovation can improve the health outcomes of Canadians.
Dr. Malik Slassi
Dr. Slassi was the Founder, President and Chief Scientific Officer of Fluorinov Pharma Inc. acquired by Trillium in January 2016. With over 25 years of experience in the successful identification of small molecule drug candidates across multiple therapeutic areas including oncology, neurology and gastro-intestinal, Dr. Slassi has advanced over 16 drug candidates into late-stage preclinical and clinical development. Dr. Slassi has over 30 years of experience in the successful identification and development of drug candidates across multiple therapeutic areas including Neurology, Psychiatry, Oncology, Immunology and Gastro-intestinal.
Dr. Harriet de Wit
Harriet de Wit, PhD, is Professor in the Department of Psychiatry and Behavioral Neuroscience at the University of Chicago. She has studied the behavioral and neurobiological effects of psychoactive drugs in human volunteers for the past 40 years. Dr. de Wit received her BA from the University of Calgary, and her PhD in Experimental Psychology at Concordia University in 1981. She has trained numerous graduate students, post-doctoral fellows and undergraduates, and published over 300 papers. She serves on editorial boards of several scientific journals and she is a consultant to the Food and Drug Administration. She has received several awards for her research, including the Distinguished Achievement Award of the European Behavioural Pharmacology Society (2019), the John F. Lemieux Medal Distinguished Alumni Award, Concordia University (2020) and the Lifetime Achievement Award from the Research Society on Alcoholism (2020).
CEO, Revive Therapeutics
Mr. Michael Frank is the Chairman of the Board and CEO of Revive. Mr. Frank has a strong background in operations, business development, M&A and the capital markets. Mr. Frank is currently the President of Mifran Consulting, providing advisory services to emerging technology companies in a number of key verticals. In the past, Mr. Frank has served as the CEO and Director of Sprylogics International and the Internet of Things Inc., as well as holding senior management positions at Ernst & Young, Data General, and NCR. Mr. Frank has had successful exits in the technology sector including one to Intuit Corporation, and has been instrumental in advising several early stage software companies including a number in the cannabis sector over the last few years.
Chairman and Chief Executive Officer, Phamather Inc.
Mr. Chianelli has over 15 years of experience with specialty life sciences companies. He was the Founder and President of Revive Therapeutics Ltd. (CSE: RVV) between 2012 and 2019. From January 2000 to January 2012, Mr. Chianelli held senior roles in investor relations, business development, and marketing and sales with Generex Biotechnology Corporation. Mr. Chianelli received his Bachelor of Commerce from Ryerson University.
Dr. Marc Afilalo, MD
Director, Emergency Medicine, Jewish General Hospital Montreal
Dr. Marc Afilalo is Director of the Emergency Multidisciplinary Research Unit (EMRU), which is comprised of a highly dynamic group of researchers conducting health services and clinical research within the emergency department. The group consists of emergency physicians, epidemiologists, statisticians, psychologists, operation management experts, industrial engineers, nurses, and medical and graduate students. It has amassed expertise in a wide variety of research areas, most notably emergency department (ED) crowding, ED operations and management, clinical trials, knowledge translation, and medical errors.
President JUUL Labs Canada
Experienced leader with a successful history of working in the food & beverages industry. Skilled in Marketing Management, Food & Beverage, Market Planning, Nielsen, and Consumer Products. Strong sales professional with a BComm focused in Finance/Mkt from University of Saskatchewan.
Dr. Christopher Harris, PhD